COMMUNIQUÉS West-GlobeNewswire

Abstract Outlining Pre-Hospital Stroke Study with Diffusion Pharmaceuticals’ TSC To Be Presented at the International Stroke Conference
24/01/2018
CHARLOTTESVILLE, Va., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN ) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on improving patient outcomes in [...]
BioCorRx Announces Collaboration with the One Day at a Time Program in Philadelphia
24/01/2018
ANAHEIM, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced a pilot [...]
TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018
24/01/2018
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX ), today announced that updated data for ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, has been [...]
FDA has approved Faron's Traumakine® IND
24/01/2018
Faron Pharmaceuticals Ltd ("Faron" or the "Company") FDA has approved Faron's Traumakine ® IND TURKU - FINLAND, 24 January 2018 - Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), the clinical stage biopharmaceutical [...]
miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum
24/01/2018
BOULDER, Colo., Jan. 24, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN ), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced [...]
pSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
24/01/2018
WATERTOWN, Mass., Jan. 24, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, will report [...]
TRIO Announces Participation in the Avoca Diligent™ Prequalification Platform
24/01/2018
EDMONTON, Alberta, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO) is pleased to announce its participation in the Avoca Diligent™ Prequalification Platform . The purpose of this initiative [...]
Anavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference
24/01/2018
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL ), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock
24/01/2018
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the pricing of an underwritten [...]
The Joint Commission, American Heart Association/American Stroke Association Announce New Thrombectomy Certification
24/01/2018
OAKBROOK TERRACE, Ill., Jan. 24, 2018 (GLOBE NEWSWIRE) -- The Joint Commission, in collaboration with the American Heart Association/American Stroke Association, the world’s leading voluntary health organization devoted [...]
Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference
24/01/2018
BERKELEY HEIGHTS, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC ) (NASDAQ: CYCCP ) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, [...]
ChromaDex to Present at the 3rd Annual NAD+ Summit
24/01/2018
IRVINE, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today it will sponsor a gathering [...]
FDA Grants Approval to Shire for Technology Transfer of CINRYZE® Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site
24/01/2018
FDA Grants Approval to Shire for Technology Transfer of CINRYZE® (C1 esterase inhibitor [human]) Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site Second production source for Cinryze drug product [...]
Green Cures & Botanical Distribution, Inc. Appoints Three Experts to Advisory Board to Focus on Cryptocurrency and Business Development
24/01/2018
LOS ANGELES, CA, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Green Cures and Botanical Distribution, Inc. (OTC PINK: GRCU), an innovative hemp-infused nutrition, botanical, sports, and body care products company, welcomes three [...]
Publishing of Orion Corporation's Financial Statement Release for 2017 on 7 February 2018
24/01/2018
ORION CORPORATION PRESS RELEASE 24 JANUARY 2018 at 11.45 A.M. EET Publishing of Orion Corporation's Financial Statement Release for 2017 on 7 February 2018 Orion will publish its Financial Statement Release for 2017 on [...]
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
24/01/2018
Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto , more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1 billion in 2017, USD 615 [...]
Novartis a enregistré, en 2017, une belle performance opérationnelle et des innovations majeures, entrant ainsi dans une nouvelle phase de croissance
24/01/2018
Hausse de 2% (tcc, +1% USD) des ventes sur l'exercice complet, car l'excellente performance de nos moteurs de croissance, notamment Cosentyx et Entresto , a plus que compensé l'érosion due aux génériques de Gleevec/ [...]
ABLYNX APPOINTS DR ROBERT FRIESEN AS CHIEF SCIENTIFIC OFFICER
24/01/2018
GHENT, Belgium, 24 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced the appointment of Robert Friesen, PhD, as Chief Scientific Officer (CSO), effective 1 March 2018. Dr Friesen will lead the [...]
Insmed Announces Pricing of Public Offering of Convertible Senior Notes
24/01/2018
BRIDGEWATER, N.J., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ) announced today that it priced its registered underwritten public offering of $400 million aggregate principal amount of its 1.75 [...]

Pages